Saari T, Strang J, Dale O
Clin Pharmacokinet. 2024; 63(4):397-422.
PMID: 38485851
PMC: 11052794.
DOI: 10.1007/s40262-024-01355-6.
Colledge-Frisby S, Rathnayake K, Nielsen S, Stoove M, Maher L, Agius P
JAMA Netw Open. 2023; 6(8):e2327319.
PMID: 37540514
PMC: 10403778.
DOI: 10.1001/jamanetworkopen.2023.27319.
Fleissner S, Stover H, Schaffer D
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2023; 66(9):1035-1041.
PMID: 37233811
PMC: 10465660.
DOI: 10.1007/s00103-023-03705-4.
Wagner N, Kempe A, Barnard J, Rinehart D, Havranek E, Glasgow R
Drug Alcohol Depend Rep. 2023; 5.
PMID: 36687307
PMC: 9851265.
DOI: 10.1016/j.dadr.2022.100094.
Olding M, Boyd J, Kerr T, Fowler A, McNeil R
Int J Drug Policy. 2022; 111:103929.
PMID: 36529032
PMC: 10184134.
DOI: 10.1016/j.drugpo.2022.103929.
UNDERSTANDING PREFERENCES FOR TYPE OF TAKE-HOME NALOXONE DEVICE: INTERNATIONAL QUALITATIVE ANALYSIS OF THE VIEWS OF PEOPLE WHO USE OPIOIDS.
Neale J, Farrugia A, Campbell A, Dietze P, Dwyer R, Fomiatti R
Drugs (Abingdon Engl). 2022; 29(2):109-120.
PMID: 35813841
PMC: 9268211.
DOI: 10.1080/09687637.2021.1872499.
Who is using take-home naloxone? An examination of supersavers.
Eide D, Lobmaier P, Clausen T
Harm Reduct J. 2022; 19(1):65.
PMID: 35717240
PMC: 9206241.
DOI: 10.1186/s12954-022-00647-z.
Naloxone protection, social support, network characteristics, and overdose experiences among a cohort of people who use illicit opioids in New York City.
Bennett A, Scheidell J, Bowles J, Khan M, Roth A, Hoff L
Harm Reduct J. 2022; 19(1):20.
PMID: 35246165
PMC: 8894821.
DOI: 10.1186/s12954-022-00604-w.
Take-home Naloxone at Opioid Treatment Programs: A Lifesaver.
Katzman J, Bhatt S, Comerci Jr G
J Addict Med. 2022; 16(6):619-621.
PMID: 35220332
PMC: 9653102.
DOI: 10.1097/ADM.0000000000000983.
Comparison of intranasal and intramuscular naloxone in opioid overdoses managed by ambulance staff: a double-dummy, randomised, controlled trial.
Skulberg A, Tylleskar I, Valberg M, Braarud A, Dale J, Heyerdahl F
Addiction. 2022; 117(6):1658-1667.
PMID: 35137493
PMC: 9302677.
DOI: 10.1111/add.15806.
Reducing the stigma surrounding opioid use disorder: evaluating an opioid overdose prevention training program applied to a diverse population.
Bascou N, Haslund-Gourley B, Amber-Monta K, Samson K, Goss N, Meredith D
Harm Reduct J. 2022; 19(1):5.
PMID: 35034649
PMC: 8761384.
DOI: 10.1186/s12954-022-00589-6.
Do naloxone access laws affect perceived risk of heroin use? Evidence from national US data.
Kelly B, Vuolo M
Addiction. 2021; 117(3):666-676.
PMID: 34617356
PMC: 8844056.
DOI: 10.1111/add.15682.
Reasons People Who Use Opioids Do Not Accept or Carry No-Cost Naloxone: Qualitative Interview Study.
Bennett A, Freeman R, Des Jarlais D, Aronson I
JMIR Form Res. 2020; 4(12):e22411.
PMID: 33355094
PMC: 7787889.
DOI: 10.2196/22411.
NTNU intranasal naloxone trial (NINA-1) study protocol for a double-blind, double-dummy, non-inferiority randomised controlled trial comparing intranasal 1.4 mg to intramuscular 0.8 mg naloxone for prehospital use.
Skulberg A, Tylleskar I, Braarud A, Dale J, Heyerdahl F, Mellesmo S
BMJ Open. 2020; 10(11):e041556.
PMID: 33184084
PMC: 7662429.
DOI: 10.1136/bmjopen-2020-041556.
Factors associated with withdrawal symptoms and anger among people resuscitated from an opioid overdose by take-home naloxone: Exploratory mixed methods analysis.
Neale J, Kalk N, Parkin S, Brown C, Brandt L, Campbell A
J Subst Abuse Treat. 2020; 117:108099.
PMID: 32811629
PMC: 7491601.
DOI: 10.1016/j.jsat.2020.108099.
Opioid overdose reversals using naloxone in New York City by people who use opioids: Implications for public health and overdose harm reduction approaches from a qualitative study.
Parkin S, Neale J, Brown C, Campbell A, Castillo F, Jones J
Int J Drug Policy. 2020; 79:102751.
PMID: 32304981
PMC: 7572435.
DOI: 10.1016/j.drugpo.2020.102751.
Preventing opioid overdose with peer-administered naloxone: findings from a rural state.
Hanson B, Porter R, Zold A, Terhorst-Miller H
Harm Reduct J. 2020; 17(1):4.
PMID: 31918740
PMC: 6953279.
DOI: 10.1186/s12954-019-0352-0.
Lessons learned from ramping up a Canadian Take Home Naloxone programme during a public health emergency: a mixed-methods study.
Young S, Williams S, Otterstatter M, Lee J, Buxton J
BMJ Open. 2019; 9(10):e030046.
PMID: 31662368
PMC: 6830612.
DOI: 10.1136/bmjopen-2019-030046.
Patient characteristics associated with being offered take home naloxone in a busy, urban emergency department: a retrospective chart review.
OBrien D, Dabbs D, Dong K, Veugelers P, Hyshka E
BMC Health Serv Res. 2019; 19(1):632.
PMID: 31488142
PMC: 6727417.
DOI: 10.1186/s12913-019-4469-3.
Take-Home Naloxone for the Emergency Interim Management of Opioid Overdose: The Public Health Application of an Emergency Medicine.
Strang J, McDonald R, Campbell G, Degenhardt L, Nielsen S, Ritter A
Drugs. 2019; 79(13):1395-1418.
PMID: 31352603
PMC: 6728289.
DOI: 10.1007/s40265-019-01154-5.
